Skip to content Skip to footer
Subscribe Now
NEWS

Novartis and Relation Therapeutics Ink ~$1.75B Atopic Disease Target-Discovery Alliance

Shots: Relation has entered into a multi-program, strategic collaboration with Novartis to identify & advance novel targets for atopic diseases, leveraging Relation’s Lab-in-the-Loop platform As per the deal, Relation will lead patient-derived observational studies to create high-resolution functional cell atlases, while Novartis will secure global development & commercialization rights to any resulting targets In return,…
December 10, 2025

Read more

NEWS

Pfizer Collaborates with YaoPharma in a ~$2.1B Licensing Deal for YP05002

Shots: Pfizer has entered into an exclusive global collaboration & license agreement with YaoPharma for YP05002, a GLP-1 receptor agonist for chronic weight management As per the deal, YaoPharma will complete the ongoing P-I trial of YP05002 & grant Pfizer exclusive global rights for further development, manufacturing & commercialization, receiving $150M upfront & ~$1.935B in…
December 10, 2025

Read more

NEWS

Alexion (AstraZeneca) and Neurimmune Expand Alliance to Develop NI009 for AL Amyloidosis

Shots: Neurimmune has entered into an exclusive global collaboration & licensing deal with Alexion to develop NI009, a preclinical human mAb for the treatment of AL amyloidosis Alexion will obtain an exclusive global license to Neurimmune’s AL amyloidosis–targeting Abs, incl. NI009, with Neurimmune handling preclinical activities, early manufacturing & the FIH study, while Alexion will…
December 5, 2025

Read more

NEWS

Regeneron and Tessera Therapeutics Enter ~$275M Collaboration to Advance TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD)

Shots: Regeneron has entered into a global collaboration with Tessera Therapeutics to develop & commercialize TSRA-196 as a one-time gene editing treatment of AATD As per the deal, Tessera & Regeneron will equally share global development costs & potential future profits for TSRA-196. Tessera will receive $150M in upfront & equity investment plus $125M in near…
December 2, 2025

Read more

NEWS

Imugene Collaborates with JW Therapeutics to Advance onCARlytics and Carteyva Combination in Solid Tumours

Shots: Imugene has entered into a co-development collaboration with JW Therapeutics to evaluate Imugene's oncolytic virus CF33-CD19 (onCARlytics) & JW's Carteyva for pts with advanced solid tumors The company will jointly perform preclinical in vitro & in vivo studies & will advance the combination to a P-I investigator-initiated trial conducted exclusively at CAR-T clinical centers…
November 28, 2025

Read more

GSK and LTZ Therapeutics
NEWS

GSK Collaborates with LTZ Therapeutics to Advance Myeloid Cell Engager Therapies in Oncology

Shots: GSK has entered into a strategic research collaboration with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) in oncology, leveraging LTZ’s immune-engager platform Under the collaboration, GSK & LTZ aim to develop up to four MCE therapies for hematologic cancers & solid tumors, with GSK receiving an exclusive option to…
November 19, 2025

Read more

Merus and Halozyme Therapeutics
NEWS

Merus Partners with Halozyme to Develop Subcutaneous Petosemtamab

Shots: Merus has entered into a global non-exclusive collaboration and license agreement with Halozyme Therapeutics to develop & commercialize SC formulation of petosemtamab using Halozyme's Enhanze drug delivery technology As per the deal, Halozyme will receive an upfront, along with commercial & sales milestones payments, plus up to low-mid single-digit royalties; Although the financial details…
November 18, 2025

Read more

NEWS

Transition Bio Inks ~$500M Pact with Voyager Therapeutics to Develop Small Molecules for Neurodegenerative Diseases

Shots: Transition Bio has entered into a drug discovery collaboration & license option agreement with Voyager Therapeutics to identify & develop selective small molecules targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS) & frontotemporal dementia As per the deal, Transition Bio will discover & optimize TDP-43–targeting small molecules, after which Voyager may license exclusive global…
November 11, 2025

Read more

NEWS

Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Shots: Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences to support development of sac-TMT, currently in 15 global P-III trials across multiple cancers, including breast, endometrial, and lung As per the deal, Blackstone will provide Merck $700M to help fund sac-TMT development through 2026. In return, Blackstone is eligible for low-to-mid…
November 5, 2025

Read more

Load more